AARD - NASDAQ
Aardvark Therapeutics, Inc. Common Stock
$3.81
-4.5%Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
At a Glance
Live SnapshotAardvark Therapeutics, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Aardvark Therapeutics, Inc. Common Stock Cash Flow Statement
AARD • NASDAQ
| Aardvark Therapeutics, Inc. Common Stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-57.6M | -20.6M | -7.2M | -13.6M | |
-1.3M | 16K | 97K | 110K | |
3.9M | 439K | 313K | 412K | |
421K | 473K | 1.1M | 3.8M | |
356K | 1.6M | -81K | -1.3M | |
-54.2M | -18.1M | -5.8M | -10.5M | |
INVESTING ACTIVITIES | ||||
-95K | -109K | (0.0) | (0.0) | |
-129.6M | -11.9M | (0.0) | (0.0) | |
80M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -1M | |
-49.7M | -12M | (0.0) | -1M | |
FINANCING ACTIVITIES | ||||
89.2M | 332K | 0.0 | 225K | |
0.0 | 0.0 | 0.0 | -1M | |
0.0 | -3.3M | 0.0 | 1M | |
89.2M | 82M | 0.0 | 225K | |
CASH FLOW SUMMARY | ||||
-14.6M | 51.9M | -5.8M | -11.3M | |
61.6M | 9.7M | 15.6M | 26.9M | |
47.1M | 61.6M | 9.7M | 15.6M | |
-54.3M | -18.2M | -5.8M | -10.5M |
SEC Filings
AARD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
S-3 S-3 N/A | March 23, 2026 | March 23, 2026 | ||
8-K 8-K 2026 N/A | February 27, 2026 | February 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 |
Related Guides
Continue your AARD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.